Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Bispecific antibody and using method thereof

A bispecific antibody and specific binding technology, applied in the direction of antibodies, chemical instruments and methods, botany equipment and methods, etc., can solve the problem of obtaining bispecific antibodies without enlightenment

Active Publication Date: 2020-03-10
GUANGXI HUIBAOYUAN PHARMA TECH CO LTD +2
View PDF17 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] However, the prior art does not suggest to obtain bispecific antibodies of the present invention comprising transmembrane domains connected in a specific tandem manner

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bispecific antibody and using method thereof
  • Bispecific antibody and using method thereof
  • Bispecific antibody and using method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073] Example 1 Preparation of bispecific antibody A of the present invention and its effect experiment

[0074] Prepared according to conventional recombinant DNA technology, in short, first construct the figure 1 The plasmid of the shown construct (pLNCX, available from Clontech Company), wherein: between the leader sequence (Leader seq) carried by the plasmid and the internal ribosome entry site (internal ribosome entry site, IRES), the coding sequence is inserted sequentially The light chain variable region and the light chain constant region (α-Tumor VL-CK, whose amino acid sequence is shown in SEQ ID NO: 4) of the anti-EGFR antibody, the linker (linker, whose amino acid sequence is GGGGSGGGGSGGGGS) and Cell adhesion molecule-1 (Intercellular Adhesion Molecule 1, ICAM-1) domain D1-D2-D3 (ICAM1-D1-3, its amino acid sequence is shown in SEQ ID NO: 1) DNA, in the second After a leader sequence (Leader seq), the heavy chain variable region encoding anti-EGFR antibody and CH...

Embodiment 2

[0080] Example 2 Preparation of the bispecific antibody C of the present invention and its effect experiment

[0081] Prepared according to conventional recombinant DNA technology, in short, first construct the Figure 5 The plasmid of the shown construct (pLNCX, available from Clontech Company), wherein: between the leader sequence (Leader seq) carried by the plasmid and the internal ribosome entry site (internal ribosome entry site, IRES), the coding sequence is inserted sequentially Anti-T cell CD3 antigen (anti-CD3) light chain variable region and light chain constant region (α-CD3 VL-CK, its amino acid sequence is shown in SEQ ID NO: 11), connecting peptide (linker, amino acid sequence GGGGSGGGGSGGGGS) and cell adhesion molecule-1 (Intercellular Adhesion Molecule 1, ICAM-1) domain D1-D2-D3 (ICAM1-D1-3, its amino acid sequence is shown in SEQ ID NO: 1) DNA, in the plasmid band In some cases, the second leader sequence (Leader seq) is sequentially inserted into the heavy c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a bispecific antibody, which comprises a first peptide chain VL-CK-TM and a second peptide chain VH-CH1-VH'-VL', wherein VH is a heavy chain variable region of the first monoclonal antibody; VL is a light chain variable region of the first monoclonal antibody; CH1 is a heavy chain constant region 1 of the first monoclonal antibody; CK is a light chain constant region of thefirst monoclonal antibody; VH' is a heavy chain variable region of the second monoclonal antibody; VL' is a light chain variable region of the second monoclonal antibody; and TM is a transmembrane protein domain. The bispecific antibody provided by the invention can especially maintain affinity to T cells for a long time, and can be used for enhancing the killing effect on cancer cells.

Description

technical field [0001] The present invention belongs to the field of antibody engineering. Specifically, the present invention relates to a bispecific antibody and its application. The bispecific antibody has excellent effects, especially the effect of maintaining the affinity of T cells for a long time. Background technique [0002] Antibodies are also called immunoglobulins (Ig). Natural antibodies contain four heterologous polypeptide chains, of which the two chains with larger molecular weight are called heavy chains (HC) and the two chains with smaller molecular weight are called light chains (LC). The regions with large changes in the amino acid sequence near the N-terminal in the light chain and heavy chain are called variable regions, that is, the light chain variable region (VL) and the heavy chain variable region (VH), which account for 1% of the heavy chain and light chain respectively. / 4 and 1 / 2, VL and VH each include three complementarity determining regions ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/46C12N15/13C12N15/85C12N5/10A61K39/395A61P35/00
CPCC07K16/468C07K16/2809C07K16/30C12N15/85A61P35/00C07K2317/92C07K2317/31A61K2039/505C07K16/46A61K39/395C12N5/10
Inventor 季匡华王愈善江欣倩黄逸君詹姆斯周
Owner GUANGXI HUIBAOYUAN PHARMA TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com